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Abstract
Introduction: Human cytomegalovirus (HCMV) establishes a persistent life-long infection, and can cause severe
pathology in the fetus and the immunocompromised host[1]. Breast milk is the primary route of transmission in
humans worldwide, and breast epithelium is thus a likely site of persistent infection and/or reactivation, though
this phenomenon has not previously been demonstrated. Increasing evidence indicates HCMV infection can
modulate signaling pathways associated with oncogenesis. We hypothesized that persistent HCMV infection occurs
in normal adult breast epithelium and that persistent viral expression might be associated with normal and
neoplastic ductal epithelium.
Methods: Surgical biopsy specimens of normal breast (n = 38) breast carcinoma (n = 39) and paired normal breast
from breast cancer patients (n = 21) were obtained. Specimens were evaluated by immunohistochemistry, in situ
hybridization, PCR and DNA sequencing for evidence of HCMV antigens and nucleic acids.
Results: We detected HCMV expression specifically in glandular epithelium in 17/27 (63%) of normal adult breast
cases evaluated. In contrast, HCMV expression was evident in the neoplastic epithelium of 31/32 (97%) patients
with ductal carcinoma in situ (DCIS) and infiltrating ductal carcinoma (IDC) cases evaluated (p = 0.0009).
Conclusions: These findings are the first to demonstrate that persistent HCMV infection occurs in breast
epithelium in a significant percentage of normal adult females. HCMV expression was also evident in neoplastic
breast epithelium in a high percentage of normal and neoplastic breast tissues obtained from breast cancer
patients, raising the possibility that viral infection may be involved in the neoplastic process.
Introduction
Environmental and epidemiological factors that contri-
bute to breast cancer are poorly understood, and only
5-20% of women with breast cancer are known to have
hereditary risk factors [2]. While investigators have
searched for viruses that contribute to breast cancer
pathogenesis, no causal associations have been estab-
lished [3]. An association of Epstein-Barr virus (EBV)
with breast cancer has been reported in the literature
[4-7]. These reports have principally relied upon use of
the DNA detection techniques of PCR and Southern
blot hybridization, but these data have not been vali-
dated with appropriately sensitive in situ techniques.
Other investigators have found that human endogenous
retroviruses with homology to mammary tumor virus
are associated with a significant percentage of breast
cancer, and can contribute to epithelial cell transforma-
tion both in vitro and in vivo[8-13]. Human papilloma
virus (HPV) is a known oncogenic virus that has been
detected in breast cancer cell lines and breast tumor
cells[14-17]. The viral proteins E6 and E7 are capable of
immortalizing normal human breast epithelial cells,
however it is unclear whether HPV has a causal role in
breast cancer[18].
Increasing evidence in the last 10 years suggests that
human cytomegalovirus (HCMV) is associated with
several human malignancies, including malignant
glioma, colorectal carcinoma, prostate cancer, and skin
cancer, and that HCMV gene products can modulate
oncogenic properties of cells in vitro [19-26]. HCMV
gene products can dysregulate cell cycle progression,
cause DNA mutations, block apoptotic pathways,
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protein functions [27-33]. Thus, cells that are persis-
tently or abortively infected with HCMV might be at
increased risk of developing genomic instability and
immunological privilege, which could accelerate
neoplastic transformation.
While evidence of HCMV in human breast glandular
tissues is lacking, breast glandular epithelium is a likely
reservoir for persistent HCMV infection in humans.
Breast milk represents an established primary route of
HCMV transmission in humans, and the shedding of
cell free virus occurs in the breast milk of over 90% of
women who are seropositive for HCMV [34-38]. Since
persistent HCMV infection of breast epithelium could,
in theory, promote malignant transformation of infected
breast epithelium, we sought to determine the detection
of HCMV gene products in normal and neoplastic
breast. To this end, we used highly sensitive immunohis-
tochemical (IHC) and in situ hybridization techniques
(ISH) to analyze archived paraffin-embedded non-neo-
plastic breast tissues (from reduction mammoplasty
patients) and breast carcinoma specimens with matched
non-neoplastic appearing breast tissues for evidence of
HCMV antigens and nucleic acids. This report is the
first to demonstrate that persistent HCMV infection
occurs in a significant percentage of non-neoplastic
breast tissues. Moreover, we find that HCMV infects a
very high percentage of both non-neoplastic and neo-
plastic breast epithelium from patients with breast
cancer.
Materials and methods
Clinical Samples
Formalin-fixed, paraffin-embedded, surgical biopsy spe-
cimens were obtained from histopathologically normal
breast tissues (from patients undergoing elective breast
reduction mammoplasty with no known history of
breast cancer), neoplastic and non-neoplastic adjacent
breast tissues from breast cancer patients from the
pathology tissue procurement archives of the University
of Alabama at Birmingham and the Birmingham Veter-
ans Affairs Hospital. The ages of breast cancer patients
ranged from 22-80, (mean = 48). Ages ranged from 20-
57 in the normal breast (reduction mammoplasty) group
(mean = 36). All samples were obtained in accordance
with ethics guidelines from the institutional review
board of each institution. A faculty pathologist (K. K.)
re-examined all cases to confirm histological diagnosis.
Since these paraffin embedded specimens were part of
the patient record, we were not allowed to exhaust the
specimen. Some specimens had only limited amounts of
tissue available, and we were therefore not able to per-
form all of the immunohistochemical and in situ hybri-
dization studies on each specimen. For this reason the
total number of specimens used exceeded the number
analyzed for any given reagent.
Immunohistochemical analyses of paraffin sections
4-μm paraffin sections were procured from biopsy speci-
mens of neoplastic and non-neoplastic breast, deparaffi-
nized in xylene, and hydrated them in graded alcohols.
Samples were processed as previously described [25]
using monoclonal antibodies for immunodetection (anti-
IE1/2 ["IE"; IgG1 isotype, 1:40, Chemicon, Temecula,
CA], anti-CMV cocktail, containing antibodies specific
for early and late antigens ["E/L"; IgG2a isotype,1:40,
Innovex Biosciences, Richmond, CA], and anti-CMV
late antigen ["L"; IgG2a isotype, 1:40, Chemicon, Teme-
cula, CA]). As controls we used anti-CD34 (1:40,
BioGenex), and anti-smooth muscle actin (1:40; Bio-
Genex, San Ramon, CA), and omission of primary anti-
body (no antibody). Immunostaining with the different
antibodies was performed in a blinded fashion with
r e s p e c tt ot i s s u ed i a g n o s i s .O n ep a t h o l o g i s t( K .K . )w h o
was blinded to the antibody used analyzed immunostain-
ing results and sections were called positive if specific
immunoreactivity was detected.
In situ hybridization of paraffin sections
To confirm that HCMV nucleic acids were present in
the pathological sections, the investigators performed in
situ hybridization with a commercially available HCMV
oligonucleotide cocktail probe labeled with fluorescein
(BioGenex/Innogenex, San Ramon, CA). This probe
consisted of six fluorescein isothiocyanate (FITC)-conju-
gated 40-mer probes spanning coding regions within the
HCMV IE1 gene, and did not hybridize with human
DNA sequences. Positive control probe specific for
human Alu DNA sequences and negative control probe
specific to an insect virus genome, both provided by the
manufacturer, were also used. 4-μm paraffin sections
were cut, deparaffinized, and hydrated through an estab-
lished series of graded ethanol. Status of fixation was
assessed for all cases before proceeding, and sections
were post-fixed in formalin if necessary. After treatment,
the prepared slides were rinsed in distilled water, dehy-
drated to 100% ethanol and air dried. Prediluted probe
was then placed onto the sections, a cover slip was
applied and slides were denatured on a MISHA thermo-
cycler (Shandon Lipshaw/Hybaid Omnigene) at 90°C for
8-10 minutes, and then hybridized at 37°C in humidified
chamber overnight. Slides were washed in TBST buffer,
subjected to probe wash (0.05% SSC buffer 20 min. at
40°C), then washed in 1× PBS. Endogenous avidin,
biotin and Fc receptors were then blocked using avidin/
biotin blocking kit (BioGenex, San Ramon, CA) and Fc
block (Innovex Biosciences, Richmond, CA). Fluorescein-
labeled probe was then detected using Supersensitive® in
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the chromogen BCIP/NBT.
PCR and DNA sequencing
DNA was purified from paraffin sections (3-6 10 μm sec-
tions) cut from a subset of the same biopsy specimens
described above using DNeasy Tissue System (Qiagen,
Valencia, CA) per manufacturer’s instructions. To avoid
potential PCR contamination, these experiments were
performed in a laboratory devoid of previous exposure to
infectious or recombinant HCMV. All preparations were
processed throughout in a blinded fashion; no positive
controls were used in any PCR reactions and blank paraf-
fin blocks were cut sequentially between each patient
sample and processed identically. For preparation of each
case, the sectioning blade was replaced and the cutting
surface was cleansed with xylene and ethanol. From each
sample, 100-250 ng of DNA was amplified by nested
PCR using internal and external primers specific for
HCMV glycoprotein B (UL55) gene as described [39].
Samples were considered positive when a band of 140 bp
size could be visualized on agarose gel with ethidium
bromide. Amplified DNA products were visualized on
1.5% agarose gels with ethidium bromide, bands were cut
out, and DNA was extracted (gel extraction kit, Qiagen,
Valencia, CA) and analyzed by automated sequencing
(ABI Model 377 DNA Sequencer, Foster City, CA). Con-
firmation of HCMV sequence was performed using a
NCBI Blast search.
Statistical analyses
Immunohistochemical data were determined in breast
tumor samples, breast tumor control samples, and nor-
mal control samples. The percentages of positive sections
for each specific monoclonal antibody in each group of
samples were estimated. Chi-square test or Fisher’se x a c t
test was applied to compare tumor samples or tumor
controls samples to normal control samples.
Results
Immunohistochemistry for HCMV
To determine whether HCMV was present in breast
epithelium from normal controls and breast cancer
patients, archived formalin fixed paraffin embedded
breast tissues were utilized. Non-neoplastic breast tis-
sues from breast reduction mammoplasty patients was
used as “non-neoplastic normal” control (N = 38). To
evaluate HCMV presence in neoplastic tissues,
the investigators obtained tumor biopsy specimens
(N = 39) and histopathologically non-neoplastic biopsy
specimens from many of the same patients ("tumor
control”, N = 21).
To detect HCMV protein expression, we performed
immunohistochemistry on as many specimens as
possible with a panel of monoclonal antibodies that
were specific to HCMV antigens expressed at different
stages of the viral life cycle. Due to limitations on the
use of archived patient specimens and/or tissue quality,
not all specimens could be evaluated for all antibodies
and in situ hybridization. The antibodies used are speci-
fic for HCMV immediate early ("IE”), early and late ("E/
L”), or late antigens ("L”) (Figures 1 and 2). As controls,
we used monoclonal antibodies specific for smooth
muscle actin (SMA) (data not shown) and CD34 (Figure
1, l). These antibodies react to smooth muscle cells and
vascular endothelial cells, respectively, but not breast
epithelial cells, and serve as IgG2a and IgG1 isotype
positive and negative monoclonal antibody controls,
respectively. As additional negative controls, we per-
formed immunostaining in the absence of primary anti-
body for all cases (data not shown).
We detected HCMV-IE antigens in neoplastic epithe-
lium from 97% of breast cancers tested while IE anti-
gens were detected in only 63% (p = 0.0009) of normal
control cases tested (Table 1, Figure 1). IE immunoreac-
tivity occurred in normal appearing ductal epithelium
(Figure 1, a-b), epithelium in DCIS, and in IDC epithe-
lial cells (Figure 2, a) evident in tumor specimens, but
IE immunoreactivity was not observed in stromal cells
(Figure 1, a-f). Immunoreactivity with the HCMV-E/L
monoclonal antibody cocktail was detected in 84% of
breast cancer specimens tested; only 21% of normal
breast controls had confirmed immunoreactivity (p <
0.0001; Table 1). The HCMV-E/L immunoreactivity was
detected in a similar cellular pattern as that of IE anti-
gen, with a staining pattern restricted to epithelium
(Figure 1, g-h; Figure 2, b). Monoclonal antibody immu-
noreactivity with HCMV-L was detected in 56% of
breast cancer specimens and 39% of normal controls
(p = 0.227; Table 1). The pattern of late antigen cellular
localization was also similar to IE and E/L immunoreac-
tivity (Figure 1, j, k; Figure 2, c). HCMV late antigen
was detected, in general, at a less intense level, although
occasional rare cells were very intensely positive for late
antigen (Figure 2, c). In some of the tumors there were
areas of homogenous low level immunoreactivity to IE,
E/L and L antigens, while in other tumors there were
scattered foci of positive tumor cells. The intensity of
immunostaining varied significantly from tumor cell to
tumor cell within any given tumor (e.g., Figure 1, j, k;
Figure 2).
In general, we detected little HCMV immunohistochem-
ical staining of stromal fibroblasts in the tumor cases. We
did, however, perform immunostaining on a subset of
tumor cases with a monoclonal antibody specific to the
HCMV pp65 tegument antigen. In several cases we
detected intense immunostaining of infiltrating stromal
macrophages with this antibody (see Additional file 1).
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Page 3 of 10Figure 1 Immunohistochemical detection of HCMV in normal breast and breast cancer. (a, b) Examples of HCMV IE immuonreactivity in
isolated area of normal ductal epithelium in normal breast from a reduction mammoplasty patient are presented. Low (a, 40×) and higher (b,
100×) power views of the same area of immunoreactive epithelium demonstrate discrete perinuclear and cytoplasmic epithelial cell staining. No
IE immunoreactivity is detected in two different specimens obtained from normal reduction mammoplasty (c and d, 40×; e is 100×
magnification of d). IE immunoreactivity is demonstrated primarily in a nuclear distribution in matched non-neoplastic epithelium from a patient
with infiltrative ductal carcinoma (f, 100×). Early and late (E/L) immunoreactivity is demonstrated in the tumor epithelial cells, but not the stroma,
from an area of ductal carcinoma in situ (DCIS) in a patient with infiltrative ductal carcinoma (g, 40×, h, 100×). Positive control immunostaining
for IE immunoreactivity is shown in HCMV infected pneumocytes from an AIDS patient with CMV pneumonia (i, 100×). Late antigen (L)
immunoreactivity is shown in another patient with infiltrative ductal carcinoma (j, 40×; k, 100×). Negative control (IE isotype control antibody
staining for CD34) immunoreactivity is seen only in vascular endothelial cells in an area of infiltrative ductal carcinoma (l, 40×).
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lium when primary antibody or monoclonal antibodies
specific for smooth muscle actin and/or CD34 were
used (Table 1), although immunoreactivity was evident
in smooth muscle cells and endothelial cells with
these antibodies as expected (e.g., Figure 1, l). The
HCMV-IE, E/L and L monoclonal antibodies were
specific for HCMV antigens when tested against
known HCMV infected lung tissues from an AIDS
patient (e.g, Figure 1, i).
Our analysis also demonstrated that there was a
higher incidence of HCMV immunoreactivity in “tumor
control” tissues from breast cancer patients than in
“normal control” tissues from breast reduction mammo-
plasty (Table 2). Interestingly, while the incidence of
HCMV IE immunoreactivity trended to a higher level in
the breast cancer patients’ control tissues compared to
the normal control tissues, it was not statistically signifi-
cant. The incidence of HCMV E/L and L immunoreac-
tivity was, however, significantly greater in the tumor
control breast tissue compared to the normal control
tissues (Table 2).
Of the tumor specimens and matched breast control
specimens from tumor patients, a total of 30 specimens
were analyzed with all three antibodies (25 tumor cases
and 5 matched controls). 22 of the true normal breast
tissues (from reduction mammoplasty) were also ana-
lyzed with all three antibodies. In all but one case where
all three antibodies were tested in the tumor specimens,
the specimens were positive for IE antibody staining
(Table 1). In 3 of these cases both the E/L and L anti-
body staining was negative, otherwise it was present. In
2 other cases either E/L or L antibody staining was
Figure 2 Immunohistochemical detection of three different HCMV antigens in a serial sections from infiltrative ductal carcinoma.
Immunoreactivity with monoclonal antibodies specific for HCMV immediate early (IE; a), early and late (E/L; b), and late (L; c) antigens is shown
in serial sections from a single specimen of infiltrative ductal carcinoma (100×).
Table 1 Comparisons of HCMV immunoreactivity in
epithelium between breast cancer and non-neoplastic
breast tissue from breast reduction mammoplasty
Tumor (N = 39) Normal Control
(N = 38)
p of Chi-Square
test
N
(examined)
+N
(examined)
+
n% n%
IE 32 31 97 27 17 63 0.0009
E/L 25 21 84 28 6 21 <0.0001
L 27 15 56 28 11 39 0.2270
No
Ab
19 0 0 20 0 0 –
CD34 16 0 0 9 0 0 –
Actin 28 0 0 29 0 0 –
Specific immunoreactivity to HCMV immediate early (IE) antigen and HCMV
early and late (E/L) antigens were significantly higher in breast cancer cases
than normal controls. Immunoreactivity to the HCMV late (L) antigen was
higher in breast cancer than normal breast. No immunoreactivity was
detected in any specimen when primary antibody was omitted. All specimens
had specific immunoreactivity to vascular endothelial cells and smooth muscle
cells with anti-CD34 and anti-smooth muscle actin antibodies, respectively,
but no immunostaining of epithelial cells was observed with these antibodies.
Table 2 Comparisons of HCMV immunoreactivity
between nonneoplatic breast tissue from known cancer
patients and non-neoplastic breast tissue from breast
reduction mammoplasty normal conrols
Tumor Control
(N = 21)
Normal Control
(N = 38)
p of Chi-Square
test
N
(examined)
+N
(examined)
+
n% n%
IE 13 12 92 27 17 63 0.0678*
E/L 15 11 73 28 6 21 0.0009
L 13 10 77 28 11 39 0.0249
No
Ab
90 0 2 0 0 0 –
CD34 6 0 0 9 0 0 –
Actin 8 0 0 29 0 0 –
* Two-sided Fisher’s exact test
Specific immunoreactivity to HCMV E/L antigens was significantly higher in
nonneoplastic breast from breast cancer cases than from breast reduction
mammoplasty controls. Immunoreactivity to the HCMV late (L) antigen was
also significantly higher in breast cancer than normal breast.
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be positive.
In contrast, while 15 of the 22 true normal breast spe-
cimens from reduction mammoplasty patients were
positive for IE antibody staining, only 7 of these 15
cases were also immunoreactive for E/L and L. These
findings suggest that HCMV early and late antigen
expression is less frequently found in normal breast tis-
sues than in tumor tissues or normal appearing breast
tissues from breast cancer patients.
To determine if the HCMV positivity rate of the tissue
samples was due to the differences in the mean age or
ethnicity of the control versus the cancer patient popu-
lations, we analyzed the data by assessing the HCMV
IE1 immuonreactivity rate of patients ≤45 years or >45
years of age. In ≤45 years group, 7 of 8 (87.5%) cancer
patients had positive HCMV IE1 antigen, compared to
12 positives of 17 (70.6%) normal tissue, and the differ-
ence was not significant. In >45 years group, all 20 can-
cer patients were positive for HCMV IE1 antigen,
compared to 4 positives out of 7 normal tissues (p =
0.012). Thus, these data remained significant for patients
>45 years of age.
There were 7 African-American patients and 31 Cau-
casian patients in the breast cancer group. There were
11 African-American and 21 Caucasian patients in the
normal breast reduction mammoplasty group. For Cau-
casians, there was no significant difference between
HCMV prevalence (95.7% in cancer tissues compared to
88.9% in normal tissues). For African-Americans,
HCMV prevalence was 100% in cancer tissues, while it
was 50% in the normal tissues. However, this difference
was not significant because of small numbers.
In situ hybridization
We performed in situ hybridization on breast cancer spe-
cimens and their paired control breast specimens, as well
as normal controls from individuals with no history of
breast cancer, to determine the presence of HCMV
nucleic acids. We detected HCMV nucleic acids specifi-
cally in neoplastic or nonneoplastic epithelial cells in 16/
18 randomly selected patients from the breast cancer pool.
In 3/3 cases that we tested both neoplastic and control
epithelium from the same patient, HCMV nucleic acids
were detected in both specimens. We also performed in
situ hybridization on 18 randomly selected “normal con-
trol” breast specimens, and 11/18 of these specimens con-
firmed specific HCMV nucleic acid detection.
The pattern of HCMV immunoreactivity was similar to
the pattern of ISH staining observed. We detected HCMV
nucleic acid hybridization in normal breast epithelium and
in neoplastic epithelium in areas of DCIS and IDC, but
HCMV nucleic acids were principally undetectable in stro-
mal cells (Figure 3, a-d). The pattern of HCMV nucleic
acid detection within the cell was distinctly different from
that of the Alu positive control probe, which is entirely
specific to cellular nuclear DNA Alu repeats (Figure 3, e).
In HCMV positive cells, we detected HCMV nucleic acids
in the nucleus but also predominantly in the cell cyto-
plasm (as shown in Figure 3, b-d, and see Additional file
2). A positive control DNA p r o b e( s p e c i f i ct oD N AA l u
repeat sequences) was specific for nuclear DNA in both
epithelial and stromal cells in DCIS/IDC in tumors and
normal breast (Figure 3, e), while a non-specific DNA
probe was non-reactive in tumor and normal tissues
(Figure 3, f). The specificity of HCMV nucleic acid hybri-
dization was confirmed by detection of HCMV infected
cells in HCMV infected lung tissues from an AIDS patient
(Figure 3, g), while a negative control probe was negative
in these same tissues (Figure 3, h). In normal breast
epithelium from reduction mammoplasty patients, the
amount of signal from HCMV nucleic acid hybridization
was, in general, dramatically less than that found in breast
tumor cells (e.g., Figure 3, i-j)
With respect to the internal consistency of immuno-
histochemical staining for HCMV antigens and detec-
tion of HCMV nucleic acids by in situ hybridization,
there was a high correlation between positive for IHC
and ISH specimens among the breast cancer and paired
controls from breast cancer patients. 16/18 cases ana-
lyzed were positive for both HCMV antigen and nucleic
acids, while in 2 cases there was a discordance (see
Additional file 3).
In the normal breast tissue from non-cancer controls,
there was a high degree of inconsistency between IHC and
ISH results. Some of the positive IHC cases were negative
for ISH, and vice versa (see Additional file 3). We attribute
these results to the overall extremely low levels of antigen
and nucleic acids detected in these normal tissues com-
pared to the cancer cases. At such low levels of antigen
and nucleic acid detection, we suspect that limitations of
detection may have resulted in lack of internally consistent
results between the two groups. In addition, it is possible
that latent HCMV infection may occur in normal breast
epithelium, in which case nucleic acids may be detected in
the absence of protein expression.
PCR and Sequencing
We performed nested PCR for HCMV UL55 gene using
DNA that was extracted from paraffin sections of 8
tumors and 4 control cases. 6/8 tumor cases and 1/4
normal control cases demonstrated amplified HCMV
UL55 gene, which was confirmed by direct sequencing
of the PCR products (not shown). Since the tumor spe-
cimens that were tested were all positive for HCMV by
immunohistochemistry, we hypothesize that the negative
PCR specimens may have had viral nucleic acids below
the level of detection for our assay, or viral genetic
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Page 6 of 10Figure 3 HCMV in situ hybridization in infiltrating ductal carcinoma. Two examples of HCMV ISH staining from two different patients with
infiltrating ductal carcinoma are displayed. Low and high power images of the first patient (a, 40×; b, 100×) demonstrate heterogeneous pattern
of detection of HCMV nucleic acids in the nuclei (dark blue) and cytoplasm (light blue) in infiltrating tumor cells but no significant nucleic acid
detection in the intervening stroma. Two images from another example of infiltrating ductal carcinoma (c, d; 100×) also reveal areas of HCMV
nucleic acid detection in nuclear (dark purple) and cytoplasmic (light purple) areas, without any significant nucleic acid detection in the
intervening stroma. Positive control probe specific for DNA Alu repeats from the same case reveals intense (dark purple) nuclear probe
hybridization with nucleic acids in infiltrating tumor nuclei and intervening stromal cells, without evidence of cytoplasmic staining (e, 100×).
Hybridization signal of a negative control probe specific to insect nucleic acids is completely absent in tumor tissues (f, 100×). Positive control
(HCMV infected lung) is positive for HCMV nucleic acid hybridization in scattered pneumocytes (blue cells in g, 100×), while negative control
probe is not detected in the same specimens (h, 100×; light hematoxylin counterstain was used in g and h). Low power image (i, 40×) of
normal breast epithelium (from reduction mammoplasty) that was negative for HCMV nucleic acid hybridization reveals no hybridization signal.
High power (j, 100×) image of normal breast epithelium from reduction mammoplasty reveals faint purple hybridization signal in scattered
normal ductal epithelial cells.
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housekeeping genes used as controls, since the DNA
quality in these assays is very variable. Alternatively, the
paraffin specimens used for these assays, which were
not necessarily sequential sections to the ones used for
immunohistochemistry and in situ hybridization, may
have had less viral genome present. The one case of
normal breast control tissue that was positive for
HCMV UL55 by PCR was also positive for HCMV by
immunohistochemistry and in situ hybridization, while
the remaining three cases were negative by all three
detection methods.
Discussion
Breastfeeding is the major route of HCMV transmission
during the first year of life in countries where most
women are seropositive and breast-feed their infants
[36]. Since cell free virus is shed in the breast milk in
virtually all HCMV seropositive females, the natural
reservoir for HCMV in the breast is likely breast glandu-
lar epithelial cells. We demonstrate here that 17/27 of
the normal breast specimens in our study from females
with no history of breast cancer exhibited evidence of
persistent HCMV infection as determined by HCMV-IE
antigen expression.
Unexpectedly, we found that 31/32 (97%) of cases of
b r e a s tc a r c i n o m ai no u rs t u d ya l s oh a v ee v i d e n c eo f
HCMV infection and expression based upon immuno-
histochemistry. Immunoreactivity to non-IE HCMV
antigens was detected in a significantly higher percen-
tage of breast cancer specimens than normal breast
cases. Overall, these data indicate that persistent HCMV
infection occurs specifically in breast glandular epithe-
lium for a significant percentage of normal adult females
and that HCMV IE protein expression is significantly
associated with neoplastic compared to nonneoplastic
breast glandular epithelium in patients over age 45 in
our group.
Our data are consistent with a previous PCR-based
report that indirectly suggested HCMV infection is pre-
sent in breast cancer [40]. In this study, the investigators
analyzed 12 specimens of normal breast from a non-
cancer group, and 62 samples of invasive ductal carci-
noma from breast cancer patients for several DNA
viruses using DNA PCR followed by Southern hybridiza-
tion [40]. The viruses analyzed included human papillo-
mavirus (HPV), HCMV, EBV, herpes simplex virus 1
(HSV-1), HSV-2, and human herpesvirus - 8 (HHV-8).
Of these six DNA viruses, only HCMV was detected in
normal breast (8/12; 67%) specimens. HCMV DNA was
also detected in 47/62 (76%) of invasive ductal carci-
noma specimens. Since in situ techniques were not used
in this study, no clear conclusion that HCMV was
located in tumor epithelial cells could be made.
Our novel findings of the expression of the IE antigen
and other gene products in normal and neoplastic breast
epithelial cells indicate that the breast epithelium is a
reservoir for persistent HCMV infection. While this
phenomenon has not been previously demonstrated, it
is not completely unexpected. HCMV is known to be
able to infect multiple organs, including the salivary
glands, lung, gastrointestinal tract, kidney, liver, spleen
and brain [41-43]. The best candidate cells for latent
infection are thought to be monocytes [44]. However,
chronic infection and expression of HCMV gene pro-
ducts in normal breast epithelium may represent a criti-
cal component of the viral life-cycle, since breast milk is
a major mode of transmission and survival for the virus.
A well known consequence of persistent viral infection
and inflammation is neoplastic transformation. Indeed,
an increasing percentage of human malignancies in the
last several decades have been attributed to chronic
infection and chronic inflammation [45]. It is well estab-
lished that chronic inflammation plays a critical role in
the transition from neoplastic precursor to full-blown
invasive malignancy, and inflammation is considered the
seventh hallmark of neoplasia [46-48]. This period of
chronic inflammation may indeed be essential for the
neoplastic process in malignancy, and may be facilitated
by infectious agents that act as “promoters”. For exam-
ple, Hepatitis C virus chronically infects the liver and
causes a persistent inflammatory immune response
resulting in hepatoma[49]. Another example is Epstein
Barr virus (EBV) in nasopharyngeal carcinoma. EBV is
ubiquitous in the human population, and thus is not
oncogenic under normal circumstances. However, EBV
infection in the nasopharynx of individuals exposed to
certain environmental carcinogens is critical in the
development of nasopharyngeal carcinoma, through
expression of latent EBV genes that promote cell growth
and survival [50].
An accumulating body of evidence indicates that
HCMV gene expression in normal epithelial cells, tumor
cells and tumor infiltrating macrophages could promote
an oncogenic environment. Multiple HCMV gene pro-
ducts are known to promote mutagenesis and to dysre-
gulate cell cycle checkpoint controls, and drive
oncogenic signaling pathways (reviewed in [26]). Recent
experimental evidence has shown that the chronic
expression of TNF-alpha and IL-1 beta in the pre-malig-
nant microenvironment in the setting of inflammation
can produce dramatic increases in the likelihood of
malignant transformation via activation of the NF-kB
transcriptional activator [51]. Furthermore, two critical
downstream effectors of this NF-kB pathway with
respect to oncogenicity appear to be COX-2 and IL-6
[49,52,53]. IL-6 induction and expression in tumor cells
and tumor associated myeloid cells has an important
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by activation of the STAT-3 transcriptional activator
[54]. Hence, the NF-kB pathway has a dual effect in
tumor promotion by preventing cell death of cells with
malignant potential and by stimulating pro-inflamma-
tory cytokines in infiltrating myeloid and lymphoid cells.
Chronic HCMV infection could potentially promote
these important oncogenic signaling pathways since
HCMV infection expresses a chemokine receptor US28,
which has oncogenic potential and has been shown to
signal through the NF-kB pathway and activate down-
stream COX-2, STAT-3 and IL-6 expression [55,56].
Indeed, an etiological role for HCMV in breast cancer
has been hypothesized based on epidemiological consid-
erations, and investigators have demonstrated that
breast cancer patients have increased IgG antibody titers
to HCMV compared to controls [57,58].
Conclusion
The data presented here indicate that HCMV infection
occurs in normal breast epithelium in a majority of
adult females evaluated and that a high percentage of
breast cancer specimens have evidence of HCMV infec-
tion. These findings suggest that further research in this
area is warranted to determine whether HCMV infec-
tion of breast epithelium represents an important factor
in the initiation and promotion of breast cancer, and
raise the possibility that in the future, antiviral based
strategies may play a role in the management of this
disease.
Additional material
Additional file 1: Immunohistochemical detection of pp65 in
infiltrating ductal carcinoma. Low and high power views of an
infiltrating ductal carcinoma demonstrating immunoreactivity to the
HCMV pp65 tegument antigen (pp65 mAb; Novocastra). Low power (a,
20×) demonstrates immunoreactivity (brown staining) in tumor cells but
not intervening stroma. However, intense immunoreactivity of
macrophages was to pp65 was detected in some cases in the outer
stromal layer (scattered brown cells). Higher power view (b, 40×)
demonstrates diffuse nuclear and cytoplasmic pp65 immunoreactivity in
infiltrating ductal tumor cells.
Additional file 2: HCMV in situ hybridization of normal breast
epithelium in infiltrative ductal carcinoma. HCMV nucleic acid
detection in an area of matched normal breast epithelium from a patient
with infiltrative ductal carcinoma reveals nuclear and cytoplasmic HCMV
nucleic acid detection in epithelial cells but not in adjacent stromal cells
(a, 100×). In an adjacent section, positive control hybridization to Alu
DNA repeats reveals intense nuclear signal from ductal epithelium,
basement membrane and stromal cells, but not cytoplasmic staining (b,
100×).
Additional file 3: Comparison of HCMV detection methods from
breast cancer samples and matched controls. Correlation of results of
immunostaining and in situ hybridization for breast cancer cases and
matched controls (A), and normal breast tissues from patients with
reduction mammoplasty (B) are reported.
List of Abbreviations
DCIS: ductal carcinoma in situ; EBV: Epstein Barr Virus; IDC: infiltrating ductal
carcinoma; IE: Immediate early; IHC: immunohistochemistry; ISH: in situ
hybridization; HCMV: human cytomegalovirus; L, late; IE/L, immediate early
and late.
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